524 related articles for article (PubMed ID: 26362172)
21. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
[TBL] [Abstract][Full Text] [Related]
22. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
23. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
[TBL] [Abstract][Full Text] [Related]
24. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
Brydak L; Roiz J; Faivre P; Reygrobellet C
Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.
Bridges CB; Thompson WW; Meltzer MI; Reeve GR; Talamonti WJ; Cox NJ; Lilac HA; Hall H; Klimov A; Fukuda K
JAMA; 2000 Oct; 284(13):1655-63. PubMed ID: 11015795
[TBL] [Abstract][Full Text] [Related]
27. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
Allsup S; Gosney M; Haycox A; Regan M
Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients.
Wongsurakiat P; Lertakyamanee J; Maranetra KN; Jongriratanakul S; Sangkaew S
J Med Assoc Thai; 2003 Jun; 86(6):497-508. PubMed ID: 12924797
[TBL] [Abstract][Full Text] [Related]
29. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
[TBL] [Abstract][Full Text] [Related]
30. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.
Richardson DM; Medvedeva EL; Roberts CB; Linkin DR;
Clin Infect Dis; 2015 Jul; 61(2):171-6. PubMed ID: 25829001
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
[TBL] [Abstract][Full Text] [Related]
33. Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season.
Shireman TI; Ogarek J; Gozalo P; Zhang T; Mor V; Davidson HE; Han L; Taljaard M; Gravenstein S
J Am Med Dir Assoc; 2019 Jul; 20(7):874-878. PubMed ID: 30777631
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
[TBL] [Abstract][Full Text] [Related]
35. Antiviral agents for influenza: a comparison of cost-effectiveness data.
Lynd LD; Goeree R; O'Brien BJ
Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
37. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
[TBL] [Abstract][Full Text] [Related]
39. Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers.
Werker GR; Sharif B; Sun H; Cooper C; Bansback N; Anis AH
Vaccine; 2014 Feb; 32(6):677-84. PubMed ID: 24355089
[TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.
Smith KJ; Nowalk MP; Lin CJ; Zimmerman RK
Hum Vaccin Immunother; 2017 Oct; 13(10):2207-2212. PubMed ID: 28829719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
